Investigation of prognostic factors for skin sclerosis and lung function in Japanese patients with early systemic sclerosis: A multicentre prospective observational study

Rheumatology

Volumn 51, Issue 1, 2012, Pages 129-133

  Hasegawa, Minoru ^a   Asano, Yoshihide ^b   Endo, Hirahito ^c   Fujimoto, Manabu ^a   Goto, Daisuke ^d   Ihn, Hironobu ^e   Inoue, Katsumi ^a   Ishikawa, Osamu ^f   Kawaguchi, Yasushi ^g   Kuwana, Masataka ^h   Muro, Yoshinao ⁱ   Ogawa, Fumihide ^j   Sasaki, Tetsuo ^k   Takahashi, Hiroki ^l   Tanaka, Sumiaki ^m   Takehara, Kazuhiko ^a   Sato, Shinichi ^b  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

^f GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^h KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^k International University of Health and Welfare   (Japan)

^l SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Interstitial lung diseases; Prognostic factor; Scleroderma; Skin sclerosis; Systemic sclerosis; Treatment

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ASSESSMENT; DEPIGMENTATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; JAPANESE; LABORATORY TEST; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SCLERODERMA; SKIN PIGMENTATION; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTINUCLEAR; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DNA TOPOISOMERASES, TYPE I; EARLY DIAGNOSIS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; JAPAN; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MOUTH; PROGNOSIS; SCLERODERMA, SYSTEMIC; SKIN; VITAL CAPACITY; YOUNG ADULT;

EID: 84855169452     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker333     Document Type: Article

References (20)

1. Silver RM. Clinical problems: the lungs. Rheum Dis Clin Nor Am 1996;22:825-40.
2. Steen VD, Conte C, Owens GR, Medsger TA. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-9.
3. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
4. Tyndall AJ, Bannert B, Vonk M et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809-15.
5. Walker UA, Tyndall A, Czirjak L et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007;66:754-63.
6. Amjadi S, Maranian P, Furst DE et al. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum 2009;60:2490-8.
7. Laing TJ, Gillespie BW, Toth MB et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997;40:734-42.
8. Nishioka K, Katayama I, Kondo H et al. Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc). Scleroderma Research Committee Japan. J Dermatol 1996;23:677-82.
9. Hamaguchi Y, Hasegawa M, Fujimoto M et al. The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol 2008;158:487-95.
10. Kuwana M, Okano Y, Kaburaki J et al. Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. Arthritis Rheum 1994;37:902-6.
11. Medsger TA Jr. Classification, purpose. In: Clements PJ, Furst DE, eds. Systemic Sclerosis. Philadelphia: Williams & Wilkins, 2004:17-28.
12. LeRoy EC, Krieg T, Black C et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
13. Committee SfSCotARADaTC. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
14. Clements P, Lachenbrush P, Seibold J et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
15. Steen VD, Powell DL, Medsger TAJ. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988;31: 196-203.
16. Kuwana M, Sato S, Kikuchi K et al. Evaluation of functional disability using the health assessment questionnaire in Japanese patients with systemic sclerosis. J Rheumatol 2003;30:1253-8.
17. Hasegawa M, Fujimoto M, Matsushita T. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol 2011;30: 231-7.
18. Steen VD, Medsger TA Jr, Osial TA Jr. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984;76:779-86.
19. Valentini G, Della Rossa A, Bombardieri S et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001;60:592-8.
20. Medsger TA Jr, Silman AJ, Steen VD et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-67.